What is the role of brolucizumab in the treatment of choroidal neovascularization (CNV)?

Updated: Jul 27, 2020
  • Author: Lihteh Wu, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print
Answer

Brolucizumab (RTH258, ESBA 1008) is the newest anti-VEGF agent to gain FDA approval. It is the smallest, with a molecular weight of 26 kDa. It is a humanized single-chain antibody fragment against all VEGF isoforms. Recent clinical trials demonstrated that brolucizumab compared favorably to aflibercept in the management of CNV due to exudative age-related macular degeneration. [47] A 2020 report suggests that brolucizumab may be associated with a higher risk of developing retinal vasculitis and intraocular inflammation. [48]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!